OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/RET
Lung Cancer — Non-Small Cell (NSCLC)RET Clinical Trials
RET fusions — most commonly KIF5B-RET and CCDC6-RET — drive 1–2% of NSCLC. Selpercatinib and pralsetinib are FDA-approved selective RET inhibitors with high response rates and intracranial activity. Trials investigate resistance mechanisms, combination strategies, and activity in RET-amplified or RET point-mutant disease.
Top recruiting RET Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
ImmunityBio, Inc.
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
More RET Lung Cancer — Non-Small Cell (NSCLC) trials
9 international trials (no US sites)
FDA-approved therapies for RET Lung Cancer — Non-Small Cell (NSCLC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.